Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, single-arm,phase Ⅱ study to evaluate the efficacy and safety of
Lenvatinib in combination with PD-1 inhibitors as first-line treatment in patients with
unresectable advanced Biliary Tract Carcinoma (BTC)